Abbott launches 3-minute, in-office A1c blood test for diagnosing diabetes

abbott
The test improves upon Abbott's previous Afinion HbA1c assay, which the FDA approved solely for monitoring long-term glycemic control at the point of care. (Image: Abbott)

Abbott has launched its new point-of-care diabetes blood test that can provide hemoglobin A1c results in only three minutes, allowing clinicians to develop and start care plans within a patient’s single visit to a doctor’s office.

The company describes the assay as the first and only rapid test cleared by the FDA for use in diagnosing diabetes or for monitoring a person’s risk for developing the condition in the future. The Afinion HbA1c Dx test is now available for use on Abbott’s Afinion 2 and AS100 analyzers.

"In addition to giving physicians the certainty of diagnosis they need to make informed decisions during a patient visit, the HbA1c Dx assay gives people living with diabetes near real-time results, so that in consultation with their doctor they can make adjustments to their lifestyle and better manage their condition,” Elizabeth Balthrop, vice president of cardiometabolic and informatics in Abbott’s Rapid Diagnostics diagnostics, said in a statement.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: ADA: Real-world data show lower A1c levels with Abbott's FreeStyle Libre CGM in Type 2 diabetes

The diagnostics assay first received FDA clearance on the AS100 analyzer in May 2018, around the same time as the launch of the Afinion 2 platform. The new test also complements the previous Afinion HbA1c assay, which was approved solely for monitoring long-term glycemic control at the point-of-care, the company said.

RELATED: Abbott notches FDA nod for first fingerprick-free CGM

Earlier this month at the annual Scientific Sessions of the American Diabetes Association, Abbott presented its first evaluation of real-world data for its FreeStyle Libre continuous glucose monitoring system in people with Type 2 diabetes.

The data showed that the system could help reduce hemoglobin A1c levels by nearly a full percentage point after three months of use among patients who had taken multiple insulin injections per day for several years.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.